A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA Non-small Cell Lung Cancer With High-risk for Relapse and no Driver Gene Mutation. (CAMFA-L)

NCT05005468 Phase 2 UNKNOWN

This is a phase II, open-label, multi-cohort study, aiming to investigate safety and efficacy of Camrelizumab combined with famitinib for adjuvant treatment of stage II-IIIA non-small cell lung cancer with high-risk for relapse and no driver gene mutation.

Details

Lead sponsor	Shanghai Chest Hospital
Phase	Phase 2
Status	UNKNOWN
Enrolment	61
Start date	2021-09
Completion	2024-08

Conditions

• NSCLC

Interventions

• Camrelizumab
• Famitinib

Primary outcomes

• DFS — 6-18 months
  Disease free survival

Countries

China